EasyM is developed by Rapid Novor.
About Us.
The EasyM™ test is being developed by Rapid Novor, a Canadian biotech company founded in 2015. The proteomics mass spectrometry and bioinformatics technology we have developed have empowered thousands of researchers to develop diagnostics, therapies, reagents, and treatments. Our vision is to elevate human health by decoding immunity. Once certified, EasyM™ will be Rapid Novor’s first proprietary clinical application of our established protein sequencing technology. As Canada’s largest privately-owned mass spectrometry proteomics facility, we are capable of processing and analyzing clinical samples from patients with Multiple Myeloma. Our team of scientists is committed to championing better testing for Multiple Myeloma. Combined, the EasyM team at Rapid Novor has decades of experience in mass spectrometry, algorithm development, process development, clinical assay development, and clinical lab management.
Meet our Myeloma Team.
Meet our Myeloma Team.
In the community.
Every year, our team meets up with our local Multiple Myeloma community in Kitchener, Ontario for the annual Multiple Myeloma March organized by Myeloma Canada. We walk 5km and we raise thousands of dollars for MM research. More importantly, we come together with clinicians, patients with MM, families and others who care about the cause. It’s a great chance for us to connect. With more awareness and more research, we can all help provide the people living with this disease with the right treatments and therapies, so they can enjoy more moments with their friends and families. Visit https://support.myeloma.ca/ for more information.